| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969820 | Vaccine | 2011 | 7 Pages |
Abstract
⺠Randomized, placebo-controlled, multicenter assessment of efficacy of baculovirus expressed hemagglutinin vaccine for prevention of laboratory-documented influenza illness in healthy adults. ⺠Vaccine was safe and generated serum hemagglutination-inhibiting antibody responses against all three components in the majority of recipients. ⺠Influenza infections during surveillance were antigenically mismatched to the components in the vaccine. ⺠Vaccine efficacy was 44.8% (95% CI, 24.4%, 60.0%) for prevention of preventing culture-confirmed influenza illness.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
John J. Treanor, Hana El Sahly, James King, Irene Graham, Ruvim Izikson, Robert Kohberger, Peter Patriarca, Manon Cox,